[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346321-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346321-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","lung-cancer-immunotherapy-in-2025-where-we-stand-and-what-comes-next","Lung cancer immunotherapy in 2025 - where we stand and what comes next","","Lung cancer remains a leading cause of cancer mortality worldwide, yet immune checkpoint inhibitors have reshaped treatment by enabling durable responses in subsets across early, locally advanced, and metastatic disease. Despite progress, only limited patients benefit long term, and barriers persist, including resistance, toxicity management, response prediction, and unequal access. This review synthesizes immunobiology, checkpoint blockade across stages, resistance mechanisms, biomarker development, and combination approaches, and evaluates emerging modalities, translational models, equity, and future directions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/lung-cancer-immunotherapy-in-2025-where-we-stand-and-what-comes-next/346321/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/lung-cancer-immunotherapy-in-2025-where-we-stand-and-what-comes-next/346321.png","ImageObject",300,407,{"name":42,"@type":43},"Himbo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What impact have immune checkpoint inhibitors had on lung cancer treatment by 2025?","Question",{"text":63,"@type":64},"Immune checkpoint inhibitors have reshaped treatment paradigms and improved outcomes across early, locally advanced, and metastatic settings for subsets of patients who can achieve long-term remissions.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why does lung cancer immunotherapy still fail for many patients?",{"text":68,"@type":64},"Most patients either do not respond initially or develop resistance after an initial response, and some tumor subtypes remain largely refractory to current immune checkpoint inhibitors.",{"name":70,"@type":61,"acceptedAnswer":71},"Which areas does the review cover to advance lung cancer immunotherapy?",{"text":72,"@type":64},"It covers lung tumor immunobiology, checkpoint blockade across disease stages, resistance mechanisms, biomarker development, combination strategies, emerging modalities, translational preclinical models, toxicity management, and issues of equity and accessibility.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346321,1791021742,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":104,"preview_page_count":33,"preview_urls":145},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","TYPE Review  \nPUBLISHED 16 January 2026  \nDOI 10.3389/fimmu.2025.1728163  \nOPEN ACCESS  \nEDITED BY  \nNethaji Muniraj,  \nChildren ’s National Hospital, United States  \nREVIEWED BY  \nAnushree Datar,  \nChildren ’s National Hospital, United States Prabhjot Kaur,  \nMorehouse School of Medicine, United States  \n*CORRESPONDENCE  \nHai Zhao  \n [yidao@qdu.edu.cn](yidao@qdu.edu.cn)  \n†These authors have contributed equally to this work  \nRECEIVED 19 October 2025  \nREVISED 12 December 2025  \nACCEPTED 12 December 2025  \nPUBLISHED 16 January 2026  \nCITATION  \nHan J, Yang Z and Zhao H (2026) Lung cancer immunotherapy in 2025: where westand and what comes next?.  \nFront. Immunol. 16:1728163 .  \ndoi: 10.3389/fimmu.2025.1728163  \nCOPYRIGHT  \n© 2026 Han, Yang and Zhao. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nLung cancer immunotherapy in 2025: where we stand and what comes next?  \nJie Han 1†, Zhibo Yang2† and Hai Zhao 3*  \n1 Department of Anesthesiology, Lanzhou University Second Hospital, Lanzhou, Gansu, China,  \n2 Department of Neurosurgery, 3201 Hospital of Xi’an Jiaotong University Health Science Center, Hanzhong, Shaanxi, China, 3 Department of Neurosurgery, The Afﬁliated Hospital of Qingdao University, Qingdao, Shandong, China  \nLung cancer continues to be the leading cause of cancer-related mortality worldwide, accounting for more deaths than breast, colorectal, and prostate cancers combined. Over the past decade, the introduction of immunotherapy has reshaped treatment paradigms, offering hope for long-term survival in a disease historically associated with dismal outcomes. The incorporation of immune checkpoint inhibitors (ICIs) into the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) has improved outcomes across early-stage, locally advanced, and metastatic settings. However, only a fraction of patients derive durable beneﬁt, and challenges remain in overcoming resistance, predicting response, managing toxicity, and ensuring equitable access. This review provides a comprehensive overview of current progress in lung cancer immunotherapy. It discusses the immunobiology of lung tumors, the role of checkpoint blockade across disease stages, mechanisms of resistance, biomarker development, and combination strategies. Emerging modalities, including bispeciﬁc antibodies, CAR-and TCR-based cellular therapies, natural killer (NK) cell platforms, cytokine agonists, oncolytic viruses, and vaccines, are explored in depth. We also evaluate the translational signiﬁcance of preclinical models, toxicity management, and issues of equity and accessibility. Finally, we outline key future directions that may redeﬁne lung cancer immunotherapy in the coming years. Collectively, these advances highlight a transition from broad applications of checkpoint inhibition toward stage-speciﬁc, biomarker-driven, and multimodal immunotherapy approaches designed to convert temporary responses into durable remissions and, ultimately, cures.  \nKEYWORDS  \nbiomarkers, CAR-T, combination therapy, immune checkpoint inhibitors, immunotherapy, lung cancer, novel modalities, resistance mechanisms  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nIntroduction  \nLung cancer represents a global health crisis, with approximately 2.2 million new cases and 1.8 million deaths annually (1–3) . Despite signiﬁcant improvements in early detection and surgical techniques, the majority of patients are diagnosed at advanced stages, where prognosis remains poor. For decades, chemotherapy was the mainstay of treatment, and although targeted t","cbCairVwo95Ovfe4","https://ap.wps.com/l/cbCairVwo95Ovfe4","pdf",5735967,"English","# Introduction\n## Scope and treatment shift by 2025","[{\"question\":\"What impact have immune checkpoint inhibitors had on lung cancer treatment by 2025?\",\"answer\":\"Immune checkpoint inhibitors have reshaped treatment paradigms and improved outcomes across early, locally advanced, and metastatic settings for subsets of patients who can achieve long-term remissions.\"},{\"question\":\"Why does lung cancer immunotherapy still fail for many patients?\",\"answer\":\"Most patients either do not respond initially or develop resistance after an initial response, and some tumor subtypes remain largely refractory to current immune checkpoint inhibitors.\"},{\"question\":\"Which areas does the review cover to advance lung cancer immunotherapy?\",\"answer\":\"It covers lung tumor immunobiology, checkpoint blockade across disease stages, resistance mechanisms, biomarker development, combination strategies, emerging modalities, translational preclinical models, toxicity management, and issues of equity and accessibility.\"}]","Lung cancer immunotherapy in 2025 - where we stand and what comes next | PDF",1790060911,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5a9fc440169b3b5afec62dd5207a457.webp",983,1389,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a642125e0e2dcdb178ce43977c457be6.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/74b26a0e717773928fe602bdebe0b18d.webp",981,1386,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9548df92fe4c0340d4e833f53f2aef82.webp",980,1385]